Ayala Pharmaceuticals, Inc. Common Stock
AYLA
AYLA was delisted on the 18th of January, 2023.
14 hedge funds and large institutions have $2.58M invested in Ayala Pharmaceuticals, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 8 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
7% less funds holding
Funds holding: 15 → 14 (-1)
12.34% less ownership
Funds ownership: 29.79% → 17.45% (-12%)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
86% less capital inflows, than outflows
Capital inflows: $288K | Capital outflows: $2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVH
Psagot Value Holdings
Tel Aviv,
Israel
|
+$82.3K |
| 2 |
CS
Clear Street
New York
|
+$53.2K |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$32K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$30.8K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$28.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$759K |
| 2 |
Citigroup
New York
|
-$444K |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$372K |
| 4 |
DAM
DLD Asset Management
New York
|
-$181K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$148K |
AYLA Hedge Fund Activity: Q3 2022 in Review
14 of the 5,831 institutional investors tracked by Wall St. Rank reported a position in Ayala Pharmaceuticals, Inc. Common Stock (AYLA) for Q3 2022, worth a combined $2.58M — down 44% from $4.57M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of AYLA and 7 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 2 added.
The largest buyer was Psagot Value Holdings, opening a new position worth an estimated $82.3K. The largest seller was Ikarian Capital, exiting entirely with an estimated $759K sold.
- 14 institutional investors held Ayala Pharmaceuticals, Inc. Common Stock (AYLA) as of Q3 2022, down from 15 in Q2 2022.
- Funds reported $2.58M of Ayala Pharmaceuticals, Inc. Common Stock stock for Q3 2022, down 44% quarter-over-quarter.
- 7 funds opened new Ayala Pharmaceuticals, Inc. Common Stock positions in Q3 2022 and 8 closed out, a net change of -1 holder.
- The largest Ayala Pharmaceuticals, Inc. Common Stock buyer in Q3 2022 was Psagot Value Holdings, an estimated $82.3K added.
- The largest Ayala Pharmaceuticals, Inc. Common Stock seller in Q3 2022 was Ikarian Capital, an estimated $759K sold.
Based on aggregated 13F filings for Q3 2022.